X
Xusheng Liu
Researcher at Guangzhou University of Chinese Medicine
Publications - 108
Citations - 1024
Xusheng Liu is an academic researcher from Guangzhou University of Chinese Medicine. The author has contributed to research in topics: Kidney disease & Medicine. The author has an hindex of 14, co-authored 90 publications receiving 619 citations.
Papers
More filters
Journal ArticleDOI
Optimized project of traditional Chinese medicine in treating chronic kidney disease stage 3: A multicenter double-blinded randomized controlled trial
Yong-jun Wang,Li-qun He,Wei Sun,Ying Lu,Xiao-qin Wang,Pei-qing Zhang,Lian-bo Wei,Shi-li Cao,Nizhi Yang,Hong-zhen Ma,Jing Gao,Ping Li,Xiao-juan Tao,Fa-Huan Yuan,Jing Li,Chen Yao,Xusheng Liu +16 more
TL;DR: For the patients with CKD stage 3, TCM can improve eGFR and hemoglobin with lower side effects and Chinese medicine integrated with benazepril can ameliorate renal function and decrease proteinuria synergistically.
Journal ArticleDOI
Accumulation of circulating advanced oxidation protein products is an independent risk factor for ischaemic heart disease in maintenance haemodialysis patients.
Qiugen Zhou,Shengjie Wu,Jianping Jiang,Jianwei Tian,Jianghua Chen,Xueqing Yu,Pingyan Chen,Changlin Mei,Fei Xiong,Wei Shi,Wei Zhou,Xusheng Liu,Shiren Sun,Di Xie,Jun Liu,Xin Xu,Min Liang,Fan Fan Hou +17 more
TL;DR: Compared the serum levels of AOPP in patients on haemodialysis and continuous ambulatory peritoneal dialysis and tested the hypothesis that an accumulation of AopP was an independent risk factor for cardiovascular disease, finding that it was not.
Journal ArticleDOI
Rhubarb Enema Improved Colon Mucosal Barrier Injury in 5/6 Nephrectomy Rats May Associate With Gut Microbiota Modification.
TL;DR: Results indicated that rhubarb enema improved the intestinal barrier, regulated gut microbiota dysbiosis, suppressed systemic inflammation, and alleviated renal fibrosis in CKD, and revealed that rheum palmatum L could restore intestinal barrier by modifying several functional enteric bacteria.
Journal ArticleDOI
China collaborative study on dialysis: a multi-centers cohort study on cardiovascular diseases in patients on maintenance dialysis
Fan Fan Hou,Fan Fan Hou,Jianping Jiang,Jianping Jiang,Jianghua Chen,Xueqing Yu,Qiugen Zhou,Qiugen Zhou,Pingyan Chen,Changlin Mei,Fei Xiong,Wei Shi,Wei Zhou,Xusheng Liu,Shiren Sun,Di Xie,Di Xie,Jun Liu,Jun Liu,Ping Zhang,Xiao Yang,Yixiang Zhang,Yanmin Zhang,Xinling Liang,Zhimin Zhang,Qizhan Lin,Yan Yu,Shengjie Wu,Shengjie Wu,Xin Xu,Xin Xu +30 more
TL;DR: Cardiovascular morbidity during chronic dialysis was more prevalent in PD than HD patients among those with old age and long-term dialysis, and metabolic disturbance-related risk factors were independently associated with CVD only in PD patients.
Journal ArticleDOI
Paeoniflorin Inhibits Mesangial Cell Proliferation and Inflammatory Response in Rats With Mesangial Proliferative Glomerulonephritis Through PI3K/AKT/GSK-3β Pathway
Bihao Liu,Jin Lin,Lixia Bai,Yuan Zhou,Ruirui Lu,Peichun Zhang,Dandan Chen,Honglian Li,Jianping Song,Xusheng Liu,Yidan Wu,Junbiao Wu,Chun-Ling Liang,Jiuyao Zhou +13 more
TL;DR: It is demonstrated that paeoniflorin ameliorates MPGN by inhibiting mesangial cell proliferation and inflammatory response through the PI3K/AKT/GSK-3β pathway.